Variable Inhibitory Effects on the Formation of Dinitrosyl Iron Complexes by Deferoxamine and Salicylaldehyde Isonicotinoyl Hydrazone in K562 Cells

REFERENCES

• Drapier JC, Pellat C, Henry Y. Generation of EPR-detectable nitrosyl-iron complexes in tumor target cells cocultured with activated macrophages. J Biol Chem 1991; 266(16)10162–10167
   PubMed Web of Science ®Google Scholar
• Bastian NR, Yim CY, Hibbs JB, Jr, Samlowski WE. Induction of iron-derived EPR signals in murine cancers by nitric oxide. Evidence for multiple intracellular targets. J Biol Chem 1994; 269(7)5127–5131
   PubMed Web of Science ®Google Scholar
• Pieper GM, Halligan NL, Hilton G, Konorev EA, Felix CC, Roza AM, Adams MB, Griffith OW. Non-heme iron protein: a potential target of nitric oxide in acute cardiac allograft rejection. Proc Natl Acad Sci USA 2003; 100(6)3125–3130
   PubMed Web of Science ®Google Scholar
• Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem J 2002; 363(Pt 3)417–429
   PubMed Web of Science ®Google Scholar
• Vanin A, Kleschyov A. EPR detection and biological implications of nitrosyl iron complexes. Nitric Oxide in Transplant Rejection and Anti-Tumor Defence, S Lukiewicz, JL Zweier. Kluwer Academic Publishing, Boston 1999; 49–82
   Google Scholar
• Ueno T, Yoshimura T. The physiological activity and in vivo distribution of dinitrosyl dithiolato iron complex. Jpn J Pharmacol 2000; 82(2)95–101
   PubMedGoogle Scholar
• Vanin AF. Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. Biochemistry (Mosc) 1998; 63(7)782–793
   PubMed Web of Science ®Google Scholar
• Keese MA, Bose M, Mulsch A, Schirmer RH, Becker K. Dinitrosyl-dithiol-iron complexes, nitric oxide (NO) carriers in vivo, as potent inhibitors of human glutathione reductase and glutathione-S-transferase. Biochem Pharmacol 1997; 54(12)1307–1313
   PubMed Web of Science ®Google Scholar
• Henry Y, Ducrocq C, Drapier JC, Servent D, Pellat C, Guissani A. Nitric oxide, a biological effector. Electron paramagnetic resonance detection of nitrosyl-iron-protein complexes in whole cells. Eur Biophys J 1991; 20(1)1–15
   PubMed Web of Science ®Google Scholar
• Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003; 531(1–2)81–92
   PubMed Web of Science ®Google Scholar
• Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 1988; 72(5)1497–1503
   PubMed Web of Science ®Google Scholar
• Laub R, Schneider YJ, Octave JN, Trouet A, Crichton RR. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem Pharmacol 1985; 34(8)1175–1183
   PubMed Web of Science ®Google Scholar
• Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 1999; 51(2)131–134
   PubMed Web of Science ®Google Scholar
• Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995; 86(11)4295–4306
   PubMed Web of Science ®Google Scholar
• Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep 2005; 4(2)110–116
   PubMedGoogle Scholar
• Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Guncova I, Kaiserova H, Palicka V, Ponka P, Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology 2007; 235(3)150–166
   PubMed Web of Science ®Google Scholar
• Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Kaiserova H, Ponka P, Gersl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity 4. J Pharmacol Exp Ther 2006; 319(3)1336–1347
   PubMed Web of Science ®Google Scholar
• Zanninelli G, Glickstein H, Breuer W, Milgram P, Brissot P, Hider RC, Konijn AM, Libman J, Shanzer A, Cabantchik ZI. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol 1997; 51(5)842–852
   PubMed Web of Science ®Google Scholar
• Kennedy MC, Antholine WE, Beinert H. An EPR investigation of the products of the reaction of cytosolic and mitochondrial aconitases with nitric oxide. J Biol Chem 1997; 272(33)20340–20347
   PubMed Web of Science ®Google Scholar
• Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 2003; 63(4)849–861
   PubMed Web of Science ®Google Scholar
• Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol 2004; 65(1)181–195
   PubMed Web of Science ®Google Scholar
• Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood 1999; 94(6)2128–2134
   PubMed Web of Science ®Google Scholar